Supernus Pharmaceuticals | SUPN - Cost Of Sales

Stock Price
51.65
Daily Change
2.28 4.62%
Monthly
0.80%
Yearly
34.51%
Q1 Forecast
50.06

Supernus Pharmaceuticals reported $43.29M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Abbott USD 4.92B 535M Dec/2025
ANI Pharmaceuticals USD 116.02M 18.12M Sep/2025
Aurora Cannabis CAD 58.08M 11.99M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Corcept Therapeutics USD 4.6M 1.16M Sep/2025
Eisai JPY 45.52B 2.92B Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Pacira USD 48.6M 6.59M Sep/2025
Perrigo USD 666.2M 27.2M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Supernus Pharmaceuticals USD 43.29M 5.64M Sep/2025
United Therapeutics USD 100.9M 74.3M Sep/2025
Xeris Pharmaceuticals USD 13.71M 1.81M Sep/2025